<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139616">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994382</url>
  </required_header>
  <id_info>
    <org_study_id>13-601</org_study_id>
    <nct_id>NCT01994382</nct_id>
  </id_info>
  <brief_title>Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma</brief_title>
  <official_title>A Phase I Open-Label, Multi-Dose, Dose Escalation Study Of PRT062070 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Or B-Cell Non Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will identify the highest dose, and assess the safety, of PRT062070 that may be
      given in patients with relapsed/refractory chronic lymphocytic leukemia or non-hodgkin
      lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of PRT062070 in patients with relapsed/refractory CLL, SLL or B-cell NHL.</measure>
    <time_frame>Approximately 84 days (baseline to end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of dose limiting toxicity (as classified by Common Terminology Criteria for Adverse Events (CTCAEv4) by dose level.</measure>
    <time_frame>Approximately 114 days (baseline to 30 days post last treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) of PRT602070.</measure>
    <time_frame>Baseline to day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Small Lymphocytic Lymphoma (SLL)</condition>
  <condition>B-cell Non Hodgkin Lymphoma (NHL)</condition>
  <arm_group>
    <arm_group_label>PRT062070</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRT062070 dose escalation study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRT062070</intervention_name>
    <description>PRT062070 oral pill</description>
    <arm_group_label>PRT062070</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have a diagnosis of CLL/SLL or B-cell Non-Hodgkin lymphoma (diffuse
             large B-cell lymphoma [DLBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL],
             MALT lymphoma, marginal zone lymphoma [MZ], lymphoplasmacytic lymphoma)

          -  Patient must be 18 years or older, of either sex, and of any race.

          -  Diagnosis of CLL/SLL or B-cell Non-Hodgkin lymphoma (diffuse large B-cell lymphoma
             [DLBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], MALT lymphoma,
             marginal zone lymphoma [MZ], lymphoplasmacytic lymphoma)

          -  Progression on at least one prior treatment regimen and no standard therapy exists

          -  ECOG Performance Score of 0 or 1.

          -  18 years or older, of either sex, and of any race.

          -  Adequate hematologic, renal and hepatic function

        Exclusion Criteria:

          -  Prior allogeneic stem cell transplant

          -  Known lymphomatous involvement of the central nervous system (CNS).

          -  Investigational therapy within 30 days or 5 half-lives

          -  Known HIV, hepatitis B or hepatitis C infection or is known to be a carrier of
             hepatitis B or C.

          -  Receiving systemic steroids at doses greater than the equivalent of prednisone, 20 mg
             daily

          -  Female and is breast-feeding, pregnant or intends to become pregnant.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Russell</last_name>
    <role>Study Director</role>
    <affiliation>Portola Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Cancer Specialists/Sarah Cannon Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Pedigo</last_name>
      <phone>615-329-7432</phone>
      <email>pedigo@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology/Sarah Cannon Research Insitute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Pedigo</last_name>
      <email>Heather.pedigo@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Ian Flinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphocytic</keyword>
  <keyword>Chronic</keyword>
  <keyword>B Cell</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
